ATE517886T1 - Pyrazolderivate - Google Patents
PyrazolderivateInfo
- Publication number
- ATE517886T1 ATE517886T1 AT06707476T AT06707476T ATE517886T1 AT E517886 T1 ATE517886 T1 AT E517886T1 AT 06707476 T AT06707476 T AT 06707476T AT 06707476 T AT06707476 T AT 06707476T AT E517886 T1 ATE517886 T1 AT E517886T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrazole derivatives
- pyrazole
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005015253A DE102005015253A1 (de) | 2005-04-04 | 2005-04-04 | Pyrazolderivate |
PCT/EP2006/002119 WO2006105844A1 (de) | 2005-04-04 | 2006-03-08 | Pyrazolderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE517886T1 true ATE517886T1 (de) | 2011-08-15 |
Family
ID=36613494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06707476T ATE517886T1 (de) | 2005-04-04 | 2006-03-08 | Pyrazolderivate |
Country Status (10)
Country | Link |
---|---|
US (1) | US7767696B2 (de) |
EP (1) | EP1866302B1 (de) |
JP (1) | JP2008534632A (de) |
AR (1) | AR053569A1 (de) |
AT (1) | ATE517886T1 (de) |
AU (1) | AU2006231002A1 (de) |
CA (1) | CA2603472A1 (de) |
DE (1) | DE102005015253A1 (de) |
ES (1) | ES2368341T3 (de) |
WO (1) | WO2006105844A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
PT1636585E (pt) | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diarilureias com actividade inibidora de cinase |
JP4777887B2 (ja) | 2003-07-23 | 2011-09-21 | バイエル、ファーマシューテイカルズ、コーポレイション | 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素 |
EP1751139B1 (de) | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
US20110195110A1 (en) * | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
US20100150863A1 (en) | 2006-12-20 | 2010-06-17 | Bayer Pharmaceuticals Corporation | Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer |
JP2010514691A (ja) * | 2006-12-20 | 2010-05-06 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 4−{4−〔({3−tert−ブチル−1−〔3−(ヒドロキシメチル)フェニル〕−1H−ピラゾール−5−イル}カルバモイル)アミノ〕−3−フルオロフェノキシ}−N−メチルピリジン−2−カルボキサミド並びに癌の治療のためのそれのプロドラッグ及び塩 |
WO2010038086A2 (en) | 2008-10-02 | 2010-04-08 | Respivert Limited | Novel compounds |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
AU2009326148B2 (en) | 2008-12-11 | 2014-05-08 | Respivert Limited | p38 MAP kinase inhibitors |
WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
US9260410B2 (en) | 2010-04-08 | 2016-02-16 | Respivert Ltd. | P38 MAP kinase inhibitors |
US9096532B2 (en) | 2010-12-13 | 2015-08-04 | The Regents Of The University Of California | Pyrazole inhibitors of COX-2 and sEH |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013046041A1 (en) | 2011-09-30 | 2013-04-04 | Synovo Gmbh | Pyridinylpyrazoles for use as kinase modulators for the treatment of cancer |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP7341060B2 (ja) | 2017-02-10 | 2023-09-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 |
WO2019133810A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
CA3140017A1 (en) * | 2019-07-19 | 2021-01-28 | Aurore HICK | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
KR20220045189A (ko) | 2019-08-12 | 2022-04-12 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양을 치료하는 방법 |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
EP4327827A3 (de) | 2019-12-30 | 2024-05-29 | Deciphera Pharmaceuticals, LLC | Amorphe kinasehemmerformulierungen und verfahren zur verwendung davon |
JP2023509628A (ja) | 2019-12-30 | 2023-03-09 | デシフェラ・ファーマシューティカルズ,エルエルシー | 1-(4-ブロモ-5-(1-エチル-7-(メチルアミノ)-2-オキソ-1,2-ジヒドロ-1,6-ナフチリジン-3-イル)-2-フルオロフェニル)-3-フェニル尿素の組成物 |
EP4029501A1 (de) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Kombination von polyaromatischen harnstoffderivaten und glucocorticoid- oder hdac-inhibitor zur behandlung von krankheiten oder störungen im zusammenhang mit muskelzellen und/oder satellitenzellen |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200002618T2 (tr) * | 1997-12-22 | 2001-04-20 | Bayer Corporation | Sübstitüe edilmiş heterosiklik üreler kullanılarak raf kinazın inhibe edilmesi |
JP2001526222A (ja) | 1997-12-22 | 2001-12-18 | バイエル コーポレイション | アリールおよびヘテロアリール置換複素環尿素を使用するp38キナーゼ活性の阻害 |
EP1041982B1 (de) | 1997-12-22 | 2011-10-19 | Bayer HealthCare LLC | HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTE HETEROCYCLISCHE HARNSTOFFE |
KR101091101B1 (ko) * | 1999-01-13 | 2011-12-09 | 바이엘 헬스케어 엘엘씨 | raf 키나아제 저해제로서의 ω-카르복시아릴 치환 디페닐 우레아 |
EP1140840B1 (de) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
ATE386030T1 (de) * | 2002-02-25 | 2008-03-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen |
DE10334663A1 (de) * | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
EP1751139B1 (de) | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
US20070078121A1 (en) * | 2004-12-23 | 2007-04-05 | Flynn Daniel L | Enzyme modulators and treatments |
-
2005
- 2005-04-04 DE DE102005015253A patent/DE102005015253A1/de not_active Withdrawn
-
2006
- 2006-03-08 AU AU2006231002A patent/AU2006231002A1/en not_active Abandoned
- 2006-03-08 ES ES06707476T patent/ES2368341T3/es active Active
- 2006-03-08 EP EP06707476A patent/EP1866302B1/de not_active Not-in-force
- 2006-03-08 AT AT06707476T patent/ATE517886T1/de active
- 2006-03-08 JP JP2008504632A patent/JP2008534632A/ja active Pending
- 2006-03-08 CA CA002603472A patent/CA2603472A1/en not_active Abandoned
- 2006-03-08 US US11/909,134 patent/US7767696B2/en not_active Expired - Fee Related
- 2006-03-08 WO PCT/EP2006/002119 patent/WO2006105844A1/de not_active Application Discontinuation
- 2006-03-31 AR ARP060101269A patent/AR053569A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2006231002A1 (en) | 2006-10-12 |
EP1866302B1 (de) | 2011-07-27 |
US7767696B2 (en) | 2010-08-03 |
US20080207699A1 (en) | 2008-08-28 |
DE102005015253A1 (de) | 2006-10-05 |
AR053569A1 (es) | 2007-05-09 |
WO2006105844A1 (de) | 2006-10-12 |
ES2368341T3 (es) | 2011-11-16 |
EP1866302A1 (de) | 2007-12-19 |
CA2603472A1 (en) | 2006-10-12 |
JP2008534632A (ja) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE517886T1 (de) | Pyrazolderivate | |
ATE475662T1 (de) | Dihydropyrazolopyrimidinonderivate | |
DK2351747T3 (da) | Fungicide N-cycloalkylbenzylamidderivater | |
ATE483711T1 (de) | Spiroindolinonderivate | |
ATE469905T1 (de) | Pyridopyrimidinonderivate | |
IS8578A (is) | 3- karbamoýl - 2- pýridón afleiður | |
ATE512135T1 (de) | Spiroindolinonderivate | |
DK1725553T3 (da) | Tetrahydropyridoindolderivater | |
ATE383361T1 (de) | Pyrrazolopyrimidinderivate | |
ATE540935T1 (de) | Chinazolinderivate | |
DK2035394T3 (da) | 2-pyrazincarboxamidderivater | |
DE602006020294D1 (de) | Heterozyklische verbindung | |
ATE417830T1 (de) | Sulfonylbenzimidazolderivate | |
DE602006010581D1 (de) | 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate | |
ATE520670T1 (de) | Pyridazinderivate | |
ATE550315T1 (de) | Pestizid-bi-phenyl-amidin-derivate | |
ATE485294T1 (de) | Azaindol-2-carboxamid-derivate | |
ATE527255T1 (de) | Aryl-isoxazol-4-yl-imidazol-derivate | |
DK1971588T3 (da) | Tiglien-3-onderivater | |
DK2086968T3 (da) | 5-hydroxymethyl-oxazolidin-2-on-derivater | |
ATE430142T1 (de) | Phenylpiperazin-methanon-derivate | |
ATE440837T1 (de) | Indazol-heteroaryl-derivate | |
ATE404542T1 (de) | 4-phenylpyrimidin-2-carbonitrilderivate | |
BRPI0820432A2 (pt) | Derivados de fenilpirazol | |
DE502006005182D1 (de) | Heterocyclylamid-substituierte imidazole |